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safe in the treatment of uncomplicated malaria in children
aged 4 months to 16 years. Arco is a suitable ACT in the332 14
New Adjunct Therapies: Endogenous inﬂammatory medi-
tors, chemokines and chemo attractant cytokines are
elieved to contribute to neurologic injury. Agents aimed
t blocking these mediators offer future therapeutic hopes:
hese have been shown to reduce brain edema, postmenin-
itic hearing loss and cochlear and brain cell injury in
xperimental meningitis. and Conclusions: In acute bac-
erial meningitis use of glycerol and maintenance instead
f restricted ﬂuids improve the outcomes; however, role
f dexamethasone in prevention of hearing loss needs re-
valuation.
oi:10.1016/j.ijid.2010.02.2230
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Background: Schistosomiasis is one of the most prevalent
arasitic diseases in developing countries and has a negative
mpact on the health of the population and consequently
he economics of those countries. In Rwanda, the mapping
urvey of schistosomiasis (and soiltransmitted helminths)
onducted in 2007 by the Neglected Tropical Disease (NTD)
ontrol program have shown that only S. mansoni was preva-
ent at 2.7% in the whole country with a variation per district
rom 0 to 69.5%. The disease was more localized near lakes
urera, Ruhondo, Muhazi and Kivu. In total, height endemic
istricts were identiﬁed and a mass drug administration with
raziquantel and albendazole was implemented.
Methods: The impact of the treatment programme was
onitored through a cohort of 2,166 school children aged 7-
6 years in ﬁve most infected districts. Their infection status
ith S. mansoni was determined by clinical and parasitologi-
al examination at baseline and at year one after treatment.
he prevalence and intensity of S. mansoni before and after
he treatment were analyzed.
Results: After one round of treatment, the prevalence of
. mansoni infection have been reduced signiﬁcantly in all 5
istricts from 11.2% [95% CI 9.8%-12.5%] at baseline to 2.0%
95% CI 1.4%-2.6%] at year one follow up. On the intensity,
he median number of eggs in the 5 districts decreased by
wo from 72 eggs per gram (epg) of stool to 36 epg. The
roportion of children with heavy S. mansoni infection was
igniﬁcantly reduced as well. Signs of early clinical morbidity
f S. mansoni infection like bloody diarrhea, abdominal pain
ecreased signiﬁcantly.The rate of hepatomegaly, which is a
ate clinical sign for S.mansoni was very low in that cohort.
t
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Conclusion: One single dose of praziquantel in school age
hildren in schistosomiasis endemic districts can decrease
igniﬁcantly the prevalence and intensity of the infection
nd can contribute to the reduction of the morbidity due to
. mansoni in Rwanda.
oi:10.1016/j.ijid.2010.02.2231
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. Rujumba1, E.A. Mworozi 1,∗, A.K. Maganda2, R. Kiguba1,
. Rwakimali 3, S. Nsobya4
Makerere University College of Health Sciences, Kampala,
ganda
Mulago National Referral Hospital, kampala, Uganda
Ministry of Health, Kampala, Uganda
Mulago Hospital, kampala, Uganda
Background: Malaria is a major cause of child morbidity
ndmortality in Uganda. It accounts for 24-45% of outpatient
isits in Uganda. The situation is worsened by the devel-
pment of drug resistance and lengthy anti-malaria drug
reatment which pose problems of compliance to medica-
ion. Both Arco and Coartem are Artemisinin Combination
herapies (ACTs). We conducted a study to compare the efﬁ-
acy and safety of Arco a single dose drug and Coartem in
he treatment of uncomplicated malaria in children aged
months — 16 years attending Mulago Hospital, Kampala
ganda.
Methods: A phase II single blinded randomized clinical
rial was carried out between November 2007 and June 2008.
e screened 3344 patients with fever for malaria of whom
53 had positive blood smear, 225 fulﬁlled the inclusion cri-
eria and were randomized into the two study arms i.e. Arco
nd Coartem arms. The study patients were followed up for
2 days.
Results: There was 100% parasite clearance by day 2 in
oth the ARCO and Coartem arms of the study. The overall
ure rate on day 42 of follow up was 98% for both Arco and
oartem. Recrudescence occurred in 2 patients in the Arco
rm of the study by day 42 and in 2 patients on Coartem
y day 21 of follow up. No statistically signiﬁcant differ-
nce in resolution of fever, vomiting, dizziness and back
ain was observed throughout the follow up period of the
tudy. No difference was observed in the clinical presenta-
ion between the two treatment arms. No serious adverse
vents were reported/observed in either of the study arms.
Conclusion: Arco and Coartem are equally effective andreatment of uncomplicated malaria in children.
oi:10.1016/j.ijid.2010.02.2232
